Effect of Combination Therapy of Canagliflozin Added to Teneligliptin Monotherapy in Japanese Subjects with Type 2 Diabetes Mellitus: A Retrospective Study.

Autor: Fushimi Y; Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Japan., Obata A; Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Japan., Sanada J; Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Japan., Iwamoto Y; Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Japan., Mashiko A; Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Japan., Horiya M; Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Japan., Mizoguchi-Tomita A; Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Japan., Nishioka M; Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Japan., Kan Y; Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Japan., Kinoshita T; Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Japan., Okauchi S; Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Japan., Hirukawa H; Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Japan., Kohara K; Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Japan., Tatsumi F; Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Japan., Shimoda M; Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Japan., Nakanishi S; Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Japan., Mune T; Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Japan., Kaku K; Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Japan., Kaneto H; Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Japan.
Jazyk: angličtina
Zdroj: Journal of diabetes research [J Diabetes Res] 2020 Apr 02; Vol. 2020, pp. 4861681. Date of Electronic Publication: 2020 Apr 02 (Print Publication: 2020).
DOI: 10.1155/2020/4861681
Abstrakt: Recently, dipeptidyl peptidase-4 (DPP-4) inhibitors and sodium-glucose cotransporter 2 (SGLT2) inhibitors have been very often used in subjects with type 2 diabetes mellitus (T2DM). In addition, combination drugs of both inhibitors have attracted much attention in aspects of its cost-effectiveness and improvement of patients' adherence. However, it is still poorly understood which factors are related to the efficacy of SGLT2 inhibitors as add-on therapy to DPP-4 inhibitors. Therefore, we aimed to elucidate in which type of individuals and/or under which conditions canagliflozin as add-on therapy to teneligliptin could exert more beneficial effects on glycemic control and/or renal protection. We retrospectively analyzed 56 Japanese subjects with T2DM in the real-world clinical practice. Three months after starting the combination therapy, the change of HbA1c ( Δ HbA1c) was strongly related to HbA1c levels at baseline. As expected, serum glucagon level was increased after starting the combination therapy. Interestingly, however, the change of glucagon levels ( Δ glucagon) was not related to HbA1c levels at baseline, Δ HbA1c, and other parameters, which indicated that the increase of glucagon did not clinically affect the effectiveness of combination therapy. In addition, the change of urinary albumin excretion ( Δ UAE) was negatively correlated with systolic blood pressure and HbA1c levels at baseline and positively correlated with the change of systolic blood pressure ( Δ sBP) in univariate analysis. Furthermore, in multivariate analysis, only Δ sBP was the independent factor associated with Δ UAE. Taken together, canagliflozin as add-on therapy to teneligliptin improves glycemic control in a Δ glucagon-independent manner and reduces UAE in a Δ sBP-dependent manner in Japanese subjects with T2DM.
Competing Interests: Hideaki Kaneto has received honoraria for lectures and received scholarship grants from Sanofi, Novo Nordisk, Lilly, Boehringer Ingelheim, MSD, Takeda, Ono Pharma, Daiichi Sankyo, Sumitomo Dainippon Pharma, Mitsubishi Tanabe Pharma, Pfizer, Kissei Pharma, AstraZeneca, Astellas, Novartis, Kowa, Chugai Pharmaceutical, and Taisho Pharmaceutical. Kohei Kaku has been an advisor to, received honoraria for lectures from, and received scholarship grants from Novo Nordisk, Sanwa Kagaku Kenkyusho, Takeda, Taisho Pharmaceutical, MSD, Kowa, Sumitomo Dainippon Pharma, Novartis, Mitsubishi Tanabe Pharma, AstraZeneca, Nippon Boehringer Ingelheim, Chugai Pharmaceutical, Daiichi Sankyo, and Sanofi. All other authors declare that they have no conflicts of interest.
(Copyright © 2020 Yoshiro Fushimi et al.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje